Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 8:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Influenza Prevention Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine Vaccine

NCT00734175
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
H6N1 Teal HK 97/AA ca recombinant vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2009 · Synced Jun 25, 2026, 8:45 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Effect of CD388 on the Immunogenicity of Fluzone® HD Vaccine

NCT07300085
View directory record Official record
Conditions
Healthy Participants
Interventions
Fluzone HD influenza vaccine, CD388 Injection, Placebo
Biological · Combination Product
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 49 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Jun 25, 2026, 8:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults

NCT00347672
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 20, 2008 · Synced Jun 25, 2026, 8:45 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

D2560C00015 FluMist Annual Safety Study 2018

NCT03564444
View directory record Official record
Conditions
Influenza, Healthy
Interventions
Bivalent influenza vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 25, 2019 · Synced Jun 25, 2026, 8:45 PM EDT
Completed Phase 1 Interventional

Vaccine for Prevention of Bird Flu

NCT00776711
View directory record Official record
Conditions
Influenza, Human
Interventions
Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005, VRC-AViDNA036-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 25, 2026, 8:45 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)

NCT01959945
View directory record Official record
Conditions
Influenza
Interventions
Flublok® Quadrivalent Influenza Virus Vaccine, Fluarix Quadrivalent® Influenza Virus Vaccine
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
6 Years to 17 Years
Enrollment
219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Auburn, Maine
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Jun 25, 2026, 8:45 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

NCT05567783
View directory record Official record
Conditions
Influenza A
Interventions
VIR-2482 (450 mg), VIR-2482 (1200 mg), Placebo
Biological
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
2,977 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
51
States / cities
Anniston, Alabama • Mobile, Alabama • Tempe, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jun 25, 2026, 8:45 PM EDT
Completed Phase 1 Interventional

Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study

NCT00646152
View directory record Official record
Conditions
Influenza, Severe Acute Respiratory Distress Syndrome, Smallpox, Ebola, Unknown Respiratory Viruses
Interventions
Poly-ICLC
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Jun 25, 2026, 8:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Influenza

NCT01175122
View directory record Official record
Conditions
Influenza A Virus Infection
Interventions
H2N3 MO 2003/AA ca Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 42 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Jun 25, 2026, 8:45 PM EDT
Completed Not applicable Interventional Results available

The Effect of Fact Versus Myth Messages on Receipt of Influenza Vaccination

NCT01009645
View directory record Official record
Conditions
Influenza Vaccination
Interventions
Fact Only Education Message, Fact and Myth Educational Message, Fact, Myth, Why Educational Message, Control Educational Message
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
50 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 29, 2023 · Synced Jun 25, 2026, 8:45 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Influenza Vaccination for Parents and Other Caregivers in the Pediatric Medical Home

NCT00812110
View directory record Official record
Conditions
Influenza
Interventions
Influenzae vaccine
Drug
Lead sponsor
Akron Children's Hospital
Other
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Jun 25, 2026, 8:45 PM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Jun 25, 2026, 8:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Group Study of the Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults

NCT00488046
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
H5N1 (6-2) AA ca Recombinant (A/Hong Kong/213/2003 x A/AnnArbor/6/60 ca)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2007 · Synced Jun 25, 2026, 8:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Immunogenicity of ND1.1 by Delivery Directly to the Ileum

NCT01698060
View directory record Official record
Conditions
Avian Influenza
Interventions
ND1.1
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Jun 25, 2026, 8:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Project to Investigate Ways to Reduce the Spread of Influenza in Schools and Households With Children

NCT00446628
View directory record Official record
Conditions
Influenza
Interventions
behaviors reducing spread of influenza
Behavioral
Lead sponsor
Kiren Mitruka
Federal
Eligibility
6 Months and older
Enrollment
3,360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Jun 25, 2026, 8:45 PM EDT
Terminated Phase 4 Interventional Results available

Test-and-treat for Influenza in Homeless Shelters

NCT04141917
View directory record Official record
Conditions
Influenza, Respiratory Viral Infection
Interventions
Point-of-care molecular testing and treatment of influenza
Combination Product
Lead sponsor
University of Washington
Other
Eligibility
3 Months and older
Enrollment
1,618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Burien, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Jun 25, 2026, 8:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine

NCT00722774
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
H2N2 1960 AA ca recombinant vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2008 · Synced Jun 25, 2026, 8:45 PM EDT
Completed Phase 3 Interventional Results available

A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older

NCT05071313
View directory record Official record
Conditions
Influenza, Human Prevention, Respiratory Syncytial Viruses Prevention
Interventions
Ad26.RSV.preF-based vaccine, Quadrivalent High-dose Influenza Vaccine, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
65 Years and older
Enrollment
777 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
19
States / cities
Long Beach, California • Hollywood, Florida • Port Orange, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Jun 25, 2026, 8:45 PM EDT
Completed Phase 1 Interventional

An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...

NCT01086657
View directory record Official record
Conditions
Influenza A Virus, H5N1 Subtype
Interventions
VRC-AVIDNA036-00-VP, Monovalent Influenza Subunit Virion (Inactive H5N1) Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 25, 2026, 8:45 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Bifidobacterium Lactis HN019 Supplementation for Prevention of Influenza Infection in Healthy Adults

NCT01258842
View directory record Official record
Conditions
Influenza
Interventions
Bifidobacterium lactis HN019, Placebo
Dietary Supplement
Lead sponsor
Fonterra Research Centre
Industry
Eligibility
18 Years to 60 Years
Enrollment
426 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Coral Gables, Florida • Rochester, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 12, 2010 · Synced Jun 25, 2026, 8:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7

NCT00922259
View directory record Official record
Conditions
Influenza A
Interventions
Influenza A H7N7 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Jun 25, 2026, 8:45 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults

NCT06863142
View directory record Official record
Conditions
Influenza Prevention, Seasonal Influenza
Interventions
VRC-FLUMOS0116-00-VP, ALFQ
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jun 25, 2026, 8:45 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age

NCT03143101
View directory record Official record
Conditions
Influenza, Healthy
Interventions
FluMist trivalent (2015-2016), FluMist Quadrivalent (2015-2016), FluMist Quadrivalent (2017-2018)
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
24 Months to 47 Months
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
12
States / cities
Savannah, Georgia • Bardstown, Kentucky • St Louis, Missouri + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Jun 25, 2026, 8:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study B)

NCT00380237
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 20, 2008 · Synced Jun 25, 2026, 8:45 PM EDT